series-a
Stage
About
Ripple Therapeutics develops polymer-free, prodrug-based sustained-release implants using its patented Epidel® platform to provide controllable, long-duration delivery of ophthalmic therapeutics for retinal diseases and glaucoma.
Explore Ripple Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.